Top Page
Smith & Nephew Snats
(NYSE:SNN)
Smith & Nephew Snats (SNN) vs. SPDR S&P 500 ETF (SPY)
Smith & Nephew Snats Business Overview & Revenue Model
Smith & Nephew Snats Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
The FlySmith & Nephew Snats Earnings Call Summary
Smith & Nephew Snats Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.18B | 5.81B | 5.55B | 5.21B | 5.21B |
| Gross Profit | 4.20B | 4.05B | 3.82B | 3.67B | 3.67B |
| EBITDA | 1.58B | 1.24B | 956.00M | 874.00M | 1.24B |
| Net Income | 626.46M | 412.00M | 263.00M | 223.00M | 524.00M |
Balance Sheet | |||||
| Total Assets | 10.46B | 10.35B | 9.99B | 9.97B | 10.92B |
| Cash, Cash Equivalents and Short-Term Investments | 557.00M | 619.00M | 302.00M | 350.00M | 1.29B |
| Total Debt | 3.33B | 3.32B | 3.08B | 2.87B | 3.34B |
| Total Liabilities | 5.17B | 5.09B | 4.77B | 4.71B | 5.35B |
| Stockholders Equity | 5.29B | 5.26B | 5.22B | 5.26B | 5.57B |
Cash Flow | |||||
| Free Cash Flow | 853.99M | 606.00M | 181.00M | 110.00M | 469.00M |
| Operating Cash Flow | 1.29B | 987.00M | 608.00M | 468.00M | 877.00M |
| Investing Cash Flow | -406.95M | -569.00M | -448.00M | -472.00M | -691.00M |
| Financing Cash Flow | -957.23M | -86.00M | -200.00M | -926.00M | -645.00M |
Smith & Nephew Snats Technical Analysis
Smith & Nephew Snats Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $47.98B | 46.44 | 10.39% | ― | 0.19% | 65.58% | |
72 Outperform | $14.11B | 22.70 | 11.79% | 2.28% | 5.78% | 61.52% | |
71 Outperform | $111.97B | 28.29 | 9.54% | 2.76% | 5.34% | 13.15% | |
68 Neutral | $105.77B | 48.91 | 12.53% | ― | 21.62% | 54.80% | |
67 Neutral | $132.34B | 41.38 | 15.04% | 0.95% | 10.95% | -18.32% | |
65 Neutral | $17.43B | 25.25 | 5.60% | 1.05% | 5.47% | -23.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Smith & Nephew Snats Corporate Events
As of 28 February 2026, Smith & Nephew plc reported total issued share capital of 877,724,845 ordinary shares of US20¢ each, of which 27,835,540 are held in treasury. This leaves 849,889,305 ordinary shares in issue carrying one voting right each.
The company highlighted that shareholders should use the 849,889,305 figure as the denominator when assessing whether they must disclose holdings or changes in holdings under the U.K. Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. The clarification, published on 2 March 2026, helps investors accurately track voting rights and ensures compliance with transparency requirements in the London market.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith+Nephew reported a strong finish to 2025, with fourth-quarter revenue rising to $1.70 billion and full-year revenue up 6.1% to $6.16 billion for the year ended 31 December 2025, alongside a 20.7% increase in operating profit and a 52.5% jump in free cash flow. Management highlighted that newer products drove broad-based growth above 5% across all three business units, while Orthopaedics posted its strongest quarterly revenue growth in more than two years.
The company announced on 2 March 2026 that it has completed its 12-Point Plan transformation, delivering margin expansion, sharply higher cash generation and improved adjusted ROIC despite portfolio rationalisation headwinds, and has launched a new RISE strategy with ambitious 2028 financial targets. Smith+Nephew also completed the acquisition of Integrity Orthopaedics to support its Sports Medicine ambitions and finished a $500 million share buyback in 2025, setting 2026 targets for faster underlying revenue growth around 6%, trading profit of about $1.3 billion including acquisition effects, strong free cash flow and further ROIC improvement, signalling confidence in accelerating growth and returns for shareholders and other stakeholders.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On 2 March 2026, Smith & Nephew reported its fourth-quarter and full-year 2025 results, showing a solid uplift in performance as revenue for 2025 rose 6.1% to $6.16 billion, trading profit climbed 15.5% to $1.21 billion, and free cash flow surged 52.5% to $840 million. The company highlighted broad-based growth across all three business units, stronger margins, robust cash generation that supported a $500 million share buyback and a higher dividend, and improved adjusted ROIC despite portfolio rationalisation.
Management declared the company’s 12-Point Plan transformation complete, citing restored orthopaedics performance, acceleration in sports medicine and advanced wound management, and a culture shift toward productivity and accountability. With the new RISE strategy launched in December 2025, new 2028 financial targets, and the completed acquisition of Integrity Orthopaedics, Smith & Nephew signalled an ambition to accelerate revenue growth, trading profit and returns in 2026 and beyond, aiming to expand its leadership in healthcare innovation and deliver sustainable value for shareholders and other stakeholders.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Smith+Nephew announced that it will publish its full-year results for the year ended 31 December 2025 on 2 March 2026 at 7:00am GMT (2:00am EST), with a follow-up conference call for financial analysts at 8:30am GMT (3:30am EST). The timetable signals the next key event in the company’s financial calendar for investors and analysts, who will be watching the results for indications of performance across its core orthopaedics, sports medicine and advanced wound management franchises and any implications for its standing in the global medtech market.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On 2 February 2026, Smith & Nephew filed a six‑monthly block listing return covering the period from 1 August 2025 to 31 January 2026, detailing the status of shares available under several employee share and incentive schemes. Across its Global Share Plan 2010, ShareSave Plans (2012 and 2022), and International ShareSave Plans (2012 and 2022), the company reported no new share allotments and unchanged balances of 3,756, 432,252, 612,504, 126,126 and 35,210 unallotted securities respectively, while under the Global Share Plan 2020 it allotted 14,695 securities, reducing the unallotted balance there to 388,563. The filing signals routine administration of its employee equity programmes, with only modest dilution from share issuance during the period and substantial headroom remaining for future grants under the various plans.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
As of 31 January 2026, Smith & Nephew plc reported a total issued share capital of 877,724,845 ordinary shares of US$0.20 each, of which 27,912,707 are held in treasury. This leaves 849,812,138 ordinary shares carrying one voting right each, a figure the company highlighted on 2 February 2026 as the key denominator for investors assessing whether they must disclose shareholdings or changes in holdings under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, ensuring clarity for shareholders and the market on current voting rights and capital structure.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On 16 January 2026, Smith & Nephew plc reported that several senior executives, including Chief Executive Officer Deepak Nath and presidents of Global Orthopaedics, Global Operations and Sports Medicine, purchased American Depositary Shares under the company’s Employee Stock Purchase Plan on the New York Stock Exchange at a price of $25.90 per share. The disclosed trades, made in line with UK Market Abuse Regulation and filed with the US Securities and Exchange Commission on 23 January 2026, indicate continued insider participation in the company’s equity compensation programme, providing investors with additional transparency over management’s equity exposure and alignment with shareholders.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On 21 January 2026, Smith+Nephew announced it had completed the acquisition of US-based Integrity Orthopaedics, an early-stage commercial developer of Tendon Seam™, a rotator cuff repair system designed to reduce re-tear rates and improve patient outcomes. The deal, structured as an initial cash payment of US$225 million with up to a further US$225 million in performance-based payments over the next five years, is positioned as a key step in executing the group’s RISE strategy to accelerate growth via strategic investments and strengthen its ambition to become the global leader in Sports Medicine, signaling an expansion of its sports medicine portfolio and a deeper push into innovative shoulder repair technologies.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On 12 January 2026, Smith+Nephew announced the acquisition of US-based Integrity Orthopaedics, an early-stage commercial developer of the Tendon Seam rotator cuff repair system, in a deal worth up to $450 million, including an initial $225 million in cash and performance-based payments over five years. The Tendon Seam technology, which received FDA 510(k) clearance in 2023, is designed to lower re-tear rates and simplify rotator cuff surgery in a US market estimated at $875 million, and will bolster Smith+Nephew’s already broad shoulder portfolio that includes the REGENETEN Bioinductive Implant, Q-FIX All-Suture Anchor and AETOS Shoulder System; financed from existing cash and expected to be accretive to trading profit margins by 2028 while keeping leverage below 2x EBITDA, the deal advances the company’s RISE growth strategy and strengthens its bid for global leadership in sports medicine shoulder repair.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
As of 31 December 2025, Smith & Nephew plc reported a total issued share capital of 877,724,845 ordinary shares of US$0.20 each, of which 27,963,140 are held in treasury, leaving 849,761,705 ordinary shares with voting rights. The company stated on 2 January 2026 that this voting share count should be used by investors as the denominator when assessing whether they must disclose holdings or changes in holdings under the UK Financial Conduct Authority’s disclosure and transparency rules, clarifying the reference base for regulatory notifications and shareholder reporting obligations.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
On December 8, 2025, Smith+Nephew announced its new RISE strategy and financial targets for 2028 at its Capital Markets Day in London. The strategy aims to elevate financial and operational performance, focusing on reaching more patients, innovating product offerings, scaling operations, and executing efficiently. The company updated its 2025 full-year guidance, expecting a trading profit margin of at least 19.5% and free cash flow around $800 million. Smith+Nephew also plans to rationalize its product portfolio, estimating a $200 million non-cash inventory provision in 2025 to simplify offerings and improve capital efficiency. The RISE strategy is expected to deliver significant shareholder value and solidify Smith+Nephew’s leadership in healthcare innovation.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.